DGAP-Adhoc: Biotest AG: Outlook revised

| Source: EQS Group AG
Biotest AG  / Key word(s): Change in Forecast

11.08.2014 20:23

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)

Outlook revised

Dreieich, August 11, 2014. The Management Board revises its outlook. A
sales increase of 7% and an operating result (EBIT) slightly above the
previous year is expected. Prior to this, an increase of 10% was planned
for both key figures.

Main reasons for the lower outlook:

The recall and the competitive situation in the US market will have a
negative impact on the sales and earnings development for the full year

Due to the political crisis in Russia and Middle East further negative
impacts on the operative business cannot be excluded.

Due to a positive development of clinical studies, (i.e. enlargement of the
clinical study IIb with tregalizumab (BT-061) including the accelerated
production of clinical study material for a phase III study as well as
accelerated production of additional clinical study material for
Civacir(R)), higher R&D expenses for the financial year 2014 are expected.

The half-year report can be downloaded from Biotest's website:

Biotest Aktiengesellschaft
The Executive Management Board

Biotest AG
Landsteinerstr. 5
D-63303 Dreieich


This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
clinical immunology, haematology and intensive medicine. Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In addition Biotest develops monoclonal antibodies
in the indications of rheumatoid arthritis and cancer of plasma cells,
which are produced by recombinant technologies. Biotest has about 1.800
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart

11.08.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

Language:     English
Company:      Biotest AG
              Landsteinerstraße 5
              63303 Dreieich
Phone:        0 61 03 - 8 01-0
Fax:          0 61 03 - 8 01-150
E-mail:       investor_relations@biotest.de
Internet:     http://www.biotest.de
ISIN:         DE0005227235, DE0005227201
WKN:          522723, 522720
Indices:      SDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, Stuttgart
End of Announcement                             DGAP News-Service